# OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

> **NCT07136012** · PHASE3 · RECRUITING · sponsor: **Amgen** · enrollment: 11000 (estimated)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** Olpasiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07136012
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2031-10-20
- **Final completion:** 2031-10-20
- **Target enrollment:** 11000 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07136012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07136012, "OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT07136012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*